Compare · CSTL vs ELV
CSTL vs ELV
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $80.92B, about 110.4x CSTL ($732.8M).
- Both names hit the wire about 9 times in the past 4 weeks.
- ELV has more recent analyst coverage (23 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $732.8M
- $80.92B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 9
- 9
- Recent ratings
- 6
- 23
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CSTL
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 550 shares at a strike of $2.39 and sold $95,622 worth of shares (4,172 units at $22.92) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
- Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
- Chief Operating Officer Oelschlager Kristen M sold $209,650 worth of shares (8,586 units at $24.42) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 21,874 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J sold $238,916 worth of shares (9,836 units at $24.29) as part of a pre-agreed trading plan and exercised 6,214 shares at a strike of $2.39 (SEC Form 4)
- SEC Form 144 filed by Castle Biosciences Inc.
- DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
- Roth Capital initiated coverage on Castle Biosciences with a new price target
- Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
- Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest ELV
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.